SOURCE: OTCPro.com

October 10, 2005 09:34 ET

Stocks to Watch: VIVI, AGEN, BCRX, CTIC

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by OTCPro.com.

BOCA RATON, FL -- (MARKET WIRE) -- October 10, 2005 -- OTCPro.com announces its list of stocks to watch! (OTC BB: VIVI), (OTC BB: AGEN), (NASDAQ: BCRX), (NASDAQ: CTIC), these stocks are looking to move!

OTCPro commenting on its continuing coverage of Viva International, Inc (OTC BB: VIVI). VIVI is up over 100% in the last 10 trading sessions and OTCPro.com believes the stock is under accumulation and poised for a major move and risk oriented traders and investors should look for a suitable entry point.

Viva International, Inc. (VIVI.OB) announced that it has executed an irrevocable Letter of Intent to Purchase the entire air carrier operation of Smyrna (Nashville), Tennessee based RegionsAir, Inc (www.regionsair.com). For the fiscal years ended December 31, 2004, RegionsAir posted operating revenues of approximately $24 million. More detailed financial data can be obtained from a review of Regions DOT filings that are available to the public.

Antigenics Inc. (NASDAQ: AGEN), the world leader in heat shock protein technology, today announced findings from its preliminary analysis of a randomized Phase 3 study of Oncophage® (vitespen; formerly HSPPC-96) in patients with metastatic melanoma. The study, which is not intended for registration, showed that in all randomized (intent-to-treat) stage IV M1a patients, median survival improved by more than 50 percent in the Oncophage-treated arm compared with those in the physician's choice treatment arm (20.9 months versus 12.8 months), which included the current array of therapies such as chemotherapeutics, biological agents and/or surgery. This is the first Phase 3 randomized trial of a cancer vaccine to show a potential survival benefit in this category of melanoma patients.

BioCryst Pharmaceuticals (BCRX ) The New York Times published an article highlighting the advantages of the company's permamivir as the most promising drug on the horizon for the treatment of avian flu.

Critical Therapeutics announces commercial launch of Zyflo (CTIC) 2.58 :CTIC announces launch of Zyflo, which is indicated for the prevention and chronic treatment of asthma in patients 12 years of age and older. Co had received FDA supplemental new drug app for Zyflo on Sept. 28. CTIC says the commercial product will be available in pharmacies the week of Oct. 17; patient starter samples will be available the week of Oct. 24. Zyflo will be priced at a wholesale acquisition cost of $7.30 per day, or $219 per month.

Morning Commentary:

Shares on Wall Street are expected to open higher on Monday as they continue to recover from a rough ride last week but trade is set to be thin with bond markets shut for Columbus Day.

The third quarter results season starts with the world's largest aluminum producer Alcoa set to post a slip in earnings per share when it reports after-hours, but bumper earnings are expected for many firms

About OTCPro.com OTCPro.com is a leading investor relations firm whose primary focus is promoting awareness among brokers, investors, and others in the investment community who are interested in small and micro-cap companies. OTCPros is dedicated to helping publicly traded companies gain the exposure they need to move forward with the development of their business plans. OTCPro's goal is to feature equity investments in micro or small capitalization companies that have the potential for long-term appreciation. OTCPro provides investors with a complete suite of online interactive financial data and tools that includes quotes, charts, company profiles, news, market commentary and SEC filings, just to name a few. OTCPros offers a free financial newsletter. To subscribe or get more information, visit our home page located at www.OTCPro.com.

OTCP, because it relies on information supplied by various third parties disclaims any responsibility for the accuracy of such information. Any investor considering making an investment in any security which has been the subject of an OTCP analysis or opinion should, before making any such investment, consult with his/her market professional and/or do his/her own independent research regarding the company which is the subject of an OTCP opinion, recommendation or analysis. Information regarding companies which OTCP has opined upon is normally available from many sources including the subject company's filings with the SEC and various press releases issued by the company.

You should be aware that OTCP is often compensated for issuing analyses, recommendations or opinions concerning particular companies. Its opinion is therefore not unbiased and you should consider this factor when evaluating OTCP's statements regarding a company. Previously OTCP's had been compensated by Market Beast LLC and Carr Holdings for the publication and circulation of this report, and received from each company 419,679 thousand free trading shares of common stock and 160,642 thousand restricted shares of VIVI.OB and OTCP and affiliates have no other relationship to companies. OTCP has been rehired by Chescom, Coby Air, Big Doug Club and DR Aeronautical and compensated 419,679 free trading shares from each company. This should be construed as a potential conflict of interest. OTCP's officers and directors reserve the right to buy additional shares of the company discussed in this opinion and may profit in the event those shares rise in value. When OTCP receives free trading shares as compensation for a profiled company, OTCP may sell part or all of any such shares during the period in which OTCP is performing such services.

Contact Information